Menu
Search
|

Menu

Close
X

Arbutus Biopharma Corp ABUS.OQ (NASDAQ Stock Exchange Global Select Market)

3.70 USD
-- (--)
As of Mar 21
chart
Previous Close 3.70
Open --
Volume --
3m Avg Volume 56,362
Today’s High --
Today’s Low --
52 Week High 12.50
52 Week Low 3.21
Shares Outstanding (mil) 56.12
Market Capitalization (mil) 277.38
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.82
Price to Sales (TTM)
vs sector
11.61
9.06
Price to Book (MRQ)
vs sector
4.01
4.61
Price to Cash Flow (TTM)
vs sector
--
40.52
Total Debt to Equity (MRQ)
vs sector
0.00
17.60
LT Debt to Equity (MRQ)
vs sector
0.00
13.95
Return on Investment (TTM)
vs sector
-51.57
12.09
Return on Equity (TTM)
vs sector
-55.72
13.20

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

100-8900 Glenlyon Pky
BURNABY   BC   V5J 5J8

Phone: +1604.4193200

Arbutus Biopharma Corp is a Canada-based biopharmaceutical company. The Company is dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company develops a portfolio of drug candidates with multiple mechanisms of action that results in a combination therapy to cure HBV. In addition to its HBV pipeline, the Company actively licenses its Lipid Nanoparticle (LNP) technology to its industry partners. This technology represents a delivery technology in RNA interference (RNAi) therapeutic development, which has enabled several clinical trials and has been administered to hundreds of human subjects.

SPONSORED STORIES